Submission Details
| 510(k) Number | K222281 FDA.gov |
| FDA Decision | Cleared SESE |
| Date Received | July 29, 2022 |
| Decision Date | October 26, 2022 |
| Days to Decision | 89 days |
| Submission Type | Traditional |
| Review Panel | Neurology (NE) |
| Summary | Summary PDF |
K222281 is an FDA 510(k) clearance for the Intracept Intraosseous Nerve Ablation System, a Probe, Radiofrequency Lesion (Class II — Special Controls, product code GXI), submitted by Relievant Medsystems, Inc. (Sunnyvale, US). The FDA issued a Cleared decision on October 26, 2022, 89 days after receiving the submission on July 29, 2022. This device falls under the Neurology review panel. Regulated under 21 CFR 882.4725.
| 510(k) Number | K222281 FDA.gov |
| FDA Decision | Cleared SESE |
| Date Received | July 29, 2022 |
| Decision Date | October 26, 2022 |
| Days to Decision | 89 days |
| Submission Type | Traditional |
| Review Panel | Neurology (NE) |
| Summary | Summary PDF |
| Product Code | GXI — Probe, Radiofrequency Lesion |
| Device Class | Class II — Special Controls |
| CFR Regulation | 21 CFR 882.4725 |